FREE UK SHIPPING ORDER BY 12:00 · SAME-DAY DISPATCH 20% FIRST REGISTERED ORDER 10% RETURNING CUSTOMER PRICING LIVE STOCK & PRICING SECURE STRIPE CHECKOUT RESEARCH USE ONLY DIRECT UK SUPPORT FREE UK SHIPPING ORDER BY 12:00 · SAME-DAY DISPATCH 20% FIRST REGISTERED ORDER 10% RETURNING CUSTOMER PRICING LIVE STOCK & PRICING SECURE STRIPE CHECKOUT RESEARCH USE ONLY DIRECT UK SUPPORT
SLSYNTRALABS
SYNTRA LABSFree UK shipping · 12:00 dispatch cutoff
FREE UK SHIPPINGAfter 12:00 · next working-day dispatchCutoff 12:00 UK
METABOLICSL-RETA30
CURRENT OFFER30% OFF
Retatrutide (RETA) 30 mg
CATALOGUE IMAGEResearch-use presentation
Home/Catalogue/RETA30
Metabolic · RETA30

Retatrutide (RETA)

30 mg

Triple hormone-receptor agonist. Presented as a catalogue material for controlled laboratory research workflows.

0130 mg vial02Triple-receptor research03Featured catalogue
CURRENT OFFER
£87.50£125.00
Save £37.50 · 30%
Live · 18 in stockAvailable from current UK catalogue stock
Server-verified priceSecure Stripe checkoutLive catalogue stockUK support
EVIDENCE ORIENTATIONClinical literature

Retatrutide is scientifically notable as a model for studying how simultaneous GIP, GLP-1 and glucagon receptor engagement changes integrated metabolic signalling.

RESEARCH DOSSIER · SL-RETA30

Retatrutide (RETA): compound context & catalogue record.

Compound-level literature, catalogue specifications and availability are deliberately separated so scientific context is not confused with product validation.

Clinical literature
CATALOGUE IDSL-RETA30Metabolic
PRESENTATION30 mgResearch vial
FOCUS AREAS3Mapped themes
REFERENCES1Selected literature
COMPOUND CLASS

Triple hormone-receptor agonist

An investigational peptide designed to activate GIP, GLP-1 and glucagon receptors within a single molecule.

EVIDENCE SUMMARY

Clinical literature

A randomized phase 2 study published in 2023 evaluated the retatrutide molecule in adults with obesity and documented its triple-receptor pharmacology. The cited evidence concerns the investigational molecule, not this catalogue material.

INTERPRETATION

Retatrutide is scientifically notable as a model for studying how simultaneous GIP, GLP-1 and glucagon receptor engagement changes integrated metabolic signalling.

Research-use information only.No section of this dossier provides medical advice, dosing, administration instructions or veterinary guidance; selected references describe the named compound or pathway and do not independently validate this catalogue item.
RELATED CATALOGUE MATERIALS

Continue within this research category.

Full catalogue →
30 mg£87.50
Retatrutide (RETA) 30 mg | Syntra Labs